COMPUMED, INC. ADDS TWO NEW BOARD MEMBERS

LOS ANGELES, May 24, 2007. CompuMed, Inc. (CMPD.OB) -- a medical informatics company leading the development of advanced imaging technology for cost effective analysis and monitoring -- today announced the appointment of Simon P. James, a consultant to Oaktree Capital Management, and Mark D. Stolper, executive vice president and chief financial officer of RadNet, Inc. (NASDAQ: RDNT), to its board of directors.

Jerry McLaughlin, CompuMed's chief executive officer, said, "I look forward to working closely with our new directors. We believe Mr. Stolper's in-depth knowledge of the imaging industry coupled with Mr. James' proven track record in international trade will bring new insights and experience to our Board of Directors that will ultimately benefit our shareholders."

Simon James is a consultant to Oaktree Capital Management, LLC, Principal Opportunities Fund. Prior to joining Oaktree in January 2005, Mr. James was an Associate Principal with McKinsey & Company, Inc., where he was responsible for developing, negotiating and leading complex strategic and operational turnarounds in a broad range of industries. Mr. James received a PhD in finance and a bachelor's degree in Natural Science from Cambridge University.

At Oaktree, Mr. James specializes on cross border opportunities - particularly those involving partnering with Chinese companies. Mr. James is also a board director of Wright Line, LLC., a leading manufacturer of technical furniture and datacenter enclosures and a portfolio company of Oaktree Capital.

Mark Stolper is the Chief Financial Officer of RadNet, Inc., a NASDAQ-listed leading owner and operator of medical diagnostic imaging centers. From January 2001 to July 2004, Mr. Stolper was a partner at Broadstream Capital Partners, LLC and West Coast Capital, a Los Angeles-based investment banking firm focused on advising middle market companies engaged in financing and merger and acquisition transactions. Prior to joining Broadstream, Mr. Stolper was responsible for business development and mergers and acquisitions for Eastman Kodak's entertainment companies and its online image licensing business, Picture Network International. Mr. Stolper has also served as a member of Archon Capital Partners, Dillon, Read & Co., Inc., and Saratoga Partners, LLP. Mr. Stolper graduated magna cum laude from the University of Pennsylvania and received a finance degree from the Wharton School.

Mr. Stolper has assisted RadNet in growing its revenue from $137 million to more than $400 million and has raised over $600 million of capital for the company. During this time, RadNet's market capitalization and stock price has expanded by more than 10 times. RadNet is leading owner and operator of freestanding medical diagnostic imaging centers in the U.S. with approximately 4,000 employees and 129 facilities in seven states. RadNet performs more than 2.5 million imaging exams each year.

Robert Stuckelman, CompuMed's chairman, said, "Our two new directors provide great strength and a clear understanding in areas where CompuMed intends to expand, including the radiology community where our OsteoGram can be coupled with the rapidly proliferating digital mammography systems. We expect that imaging centers will soon offer bone density screening in conjunction with mammography, since many women getting mammograms are also candidates for osteoporosis screening. In addition we are gaining a wealth of experience in strategic planning and international business."

About CompuMed:

Founded in 1973, CompuMed, Inc. (CMPD.OB) is leading the development of advanced imaging and medical informatics solutions that provide cost effective analysis and monitoring. CompuMed focuses on cardiovascular and musculoskeletal diseases, as well as other diseases associated with aging populations. Its unique expertise in telemonitoring, imaging and analysis facilitates the development of new solutions and services designed to improve healthcare provider workflow and patient care, while reducing costs. CompuMed's core products, the OsteoGramŽ and CardioGram^TM systems, are cleared by the FDA and reimbursable by Medicare. The OsteoGram is an accurate and precise technology for osteoporosis testing. The underlying OsteoGram technology has significant cost advantages over other technologies and will be applied to a suite of value-added applications, such as following the progression of arthritic disease and diagnosing vertebral fractures and scoliosis. The CardioGram system is one of the first telecommunication networks designed to remotely interpret electrocardiograms, and is used by private practice, as well as government and corporate healthcare providers nationwide. The CardioGram delivers online electrocardiogram interpretations within two minutes of receipt, and has the additional capability to automatically provide an over-read (i.e., follow-up review) by a cardiologist. CompuMed is headquartered in Los Angeles. Visit CompuMed at www.compumed.net.

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning CompuMed's plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are not statements of historical fact. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, ability to raise capital, the availability of appropriate acquisition candidates and/or business partnerships, economic conditions, the impact of competition and pricing, capacity and supply constraints or difficulties, government regulation and other risks identified in the Company's filings with the Securities and Exchange Commission. All such forward-looking statements are expressly qualified by these cautionary statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

CONTACT: Susan Tellem - Tellem Worldwide, +1 (310) 479-6111 x.16.